Evidence map›Paper›PMID 29946683›Full record

Observational studyAnnals of internal medicine2018

Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.

Jonathan L Chang, Alexander C Tsai, Nicholas Musinguzi, Jessica E Haberer, Yap Boum, Conrad Muzoora, Mwebesa Bwana, Jeffrey N Martin, Peter W Hunt, David R Bangsberg and 1 more

Registry-linked trialAbstract readCase ReportsObservational Study
In one paragraph

Observational study in Annals of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01596322 (Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01596322 completednot on this map

Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda

TypeobservationalSponsorMassachusetts General HospitalRan2004 to 2015Enrolled750ConditionsHIV/AIDS
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The Potential ofNutrients · 2022
    Review
  5. Sexual Risk Behavior and Lifetime HIV Testing: The Role of Adverse Childhood Experiences.International journal of environmental research and public health · 2022
    Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Observational
  11. Observational
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Jonathan L ChangDuke University School of Medicine, Durham, North Carolina, and Massachusetts General Hospital, Boston, Massachusetts (J.L.C.).
Alexander C TsaiMbarara University of Science and Technology, Mbarara, Uganda (A.C.T., N.M., C.M., M.B.).
Nicholas MusinguziMbarara University of Science and Technology, Mbarara, Uganda (A.C.T., N.M., C.M., M.B.).
Jessica E HabererMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (J.E.H.).
Yap BoumMbarara University of Science and Technology, Mbarara, Uganda; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Epicentre Mbarara, Mbarara, Uganda (Y.B.).
Conrad MuzooraMbarara University of Science and Technology, Mbarara, Uganda (A.C.T., N.M., C.M., M.B.).
Mwebesa BwanaMbarara University of Science and Technology, Mbarara, Uganda (A.C.T., N.M., C.M., M.B.).
Jeffrey N MartinUniversity of California, San Francisco, San Francisco, California (J.N.M., P.W.H.).
Peter W HuntUniversity of California, San Francisco, San Francisco, California (J.N.M., P.W.H.).
David R BangsbergMbarara University of Science and Technology, Mbarara, Uganda, and Oregon Health & Science University, Portland, Oregon (D.R.B.).
Mark J SiednerMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Mbarara University of Science and Technology, Mbarara, Uganda (M.J.S.).
Mbarara University of Science and Technology · UGHarvard University · USUniversity of California, San Francisco · USDuke University Hospital · USMassachusetts General Hospital · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
TB PREVENTION AND HIV IN THE HOMELESS--AN INTERVENTIONR01MH054907 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANGSBERG, DAVID ROY · 1995 to 2014
$20.7M
West Coast AIDS and Cancer Specimen Resource (ACSR)U01CA066529 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCGRATH, MICHAEL SHANNON · 1994 to 2012
$16.1M
Behavioral Aspects of Low-cost Medical Devices to Improve HIV CareK23MH099916 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI SIEDNER, MARK J · 2013 to 2017
$917k
NCI NIH HHS U01 CA066529NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI060354NIMH NIH HHS K23 MH099916NIMH NIH HHS R01 MH054907
6 · The paper itself

Abstract

Background: Evidence regarding potential adverse neuropsychiatric effects of efavirenz is conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) reside and efavirenz is used as first-line therapy, are limited. Objective: To estimate associations between efavirenz use and depression and suicidal ideation among PLHIV in Uganda. Design: Prospective observational cohort study. (ClinicalTrials.gov: NCT01596322). Setting: Mbarara, Uganda. Participants: Adult PLHIV enrolled at the start of antiretroviral therapy (ART) and observed every 3 to 4 months from 2005 to 2015. Measurements: The exposure of interest was time-varying efavirenz use, defined as use during the 7 days and in 60 or more of the 90 days before a study visit, compared with nevirapine use. Self-reported outcomes were depression, defined as a mean score greater than 1.75 on the Hopkins Symptom Checklist depression subscale, and suicidal ideation. Multivariable-adjusted generalized estimating equations (GEE) logistic regression, Cox proportional hazards regression, and marginal structural models were fit to estimate the association between efavirenz use and the risk for depression and suicidal ideation. Results: 694 participants (median age, 33 years; median pretreatment CD4+ count, 1.8 × 109 cells/L) contributed 1200 person-years of observation (460 person-years receiving efavirenz). No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0.80 for both). Of 305 participants ever-exposed to efavirenz, 61 (20.0%) and 19 (6.2%) had depression and suicidal ideation, respectively, on at least 1 follow-up visit, compared with 125 (32.1%) and 47 (12.1%) of the 389 who received nevirapine. In adjusted GEE models, efavirenz use was associated with decreased odds of depression compared with nevirapine use (adjusted odds ratio, 0.62 [95% CI, 0.40 to 0.96]) and was not significantly associated with suicidal ideation (adjusted odds ratio, 0.61 [CI, 0.30 to 1.25]). Time-to-event and marginal structural models yielded similar estimates. Limitation: Nonrandom assignment to treatment and substantial differences between the efavirenz and nevirapine groups. Conclusion: No evidence was found that use of efavirenz in first-line ART increased the risk for depression or suicidal ideation compared with nevirapine use among PLHIV in Uganda. Primary Funding Source: National Institutes of Health.

Indexed as

Suicidal IdeationAdultAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesDepressionFemaleHIV InfectionsHumansMaleNevirapineProspective StudiesUgandaAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesefavirenzNevirapine

Identifiers

PMID29946683
PMCPMC6475600
OpenAlexW2810931264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.